Stephen Bloch Sells 100,000 Shares of Liquidia (NASDAQ:LQDA) Stock

Liquidia Corporation (NASDAQ:LQDA) Director Stephen Bloch sold 100,000 shares of Liquidia stock in a transaction dated Thursday, July 23rd. The stock was sold at an average price of $89.48, for a total value of $8,948,000.00. Following the completion of the transaction, the director owned 501,477 shares of the company’s stock, valued at $44,872,161.96. This trade represents a 16.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Liquidia Price Performance

Shares of NASDAQ LQDA opened at $86.82 on Thursday. The company has a current ratio of 2.22, a quick ratio of 2.03 and a debt-to-equity ratio of 1.18. Liquidia Corporation has a twelve month low of $16.82 and a twelve month high of $91.10. The business has a 50 day simple moving average of $72.81 and a 200-day simple moving average of $51.36. The company has a market capitalization of $7.72 billion, a price-to-earnings ratio of 620.19 and a beta of 0.55.

Liquidia (NASDAQ:LQDA) last issued its earnings results on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.11. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The company had revenue of $132.87 million for the quarter, compared to analysts’ expectations of $119.44 million. Liquidia’s revenue for the quarter was up 4187.1% compared to the same quarter last year. As a group, equities research analysts expect that Liquidia Corporation will post 3.02 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. HC Wainwright set a $36.00 price target on shares of Liquidia in a research note on Friday, July 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Liquidia in a research report on Friday, July 17th. BTIG Research raised their price objective on shares of Liquidia from $59.00 to $109.00 and gave the company a “buy” rating in a research report on Monday, June 22nd. Wells Fargo & Company raised their price objective on Liquidia from $51.00 to $62.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 12th. Finally, Royal Bank Of Canada set a $130.00 target price on shares of Liquidia in a report on Friday, July 24th. Three analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $86.18.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Covestor Ltd increased its stake in shares of Liquidia by 41.9% during the 4th quarter. Covestor Ltd now owns 1,216 shares of the company’s stock worth $42,000 after purchasing an additional 359 shares during the last quarter. PNC Financial Services Group Inc. grew its stake in Liquidia by 7.2% in the 4th quarter. PNC Financial Services Group Inc. now owns 6,304 shares of the company’s stock valued at $217,000 after buying an additional 422 shares during the last quarter. Quantinno Capital Management LP raised its holdings in Liquidia by 3.6% in the 1st quarter. Quantinno Capital Management LP now owns 17,165 shares of the company’s stock worth $648,000 after acquiring an additional 589 shares during the period. Northwestern Mutual Wealth Management Co. acquired a new position in shares of Liquidia during the 4th quarter worth about $25,000. Finally, ProShare Advisors LLC lifted its holdings in shares of Liquidia by 7.1% during the fourth quarter. ProShare Advisors LLC now owns 11,756 shares of the company’s stock worth $405,000 after buying an additional 775 shares during the last quarter. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Liquidia News Summary

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia will report its second-quarter 2026 financial results on August 12, 2026. The update should provide investors with insight into YUTREPIA sales, operating performance and the company’s outlook. Liquidia Second Quarter 2026 Results Announcement
• Positive Sentiment: LifeSci Capital maintained a Buy rating, while Buckley Capital Advisors cited potential upside of more than 50% based on a prospective YUTREPIA ruling and possible buyout interest. These views support the bullish case, although they depend on regulatory and strategic outcomes. LifeSci Capital Buy Rating Buckley Capital Liquidia Investor Letter
• Neutral Sentiment: Recent coverage highlights a valuation debate: YUTREPIA could drive substantial growth, but patent risks and the stock’s elevated valuation may limit further gains. Shares trade at roughly 620 times earnings, making execution especially important.
• Negative Sentiment: Several insiders reported sales. Director Stephen Bloch sold 178,596 shares for about $15.2 million across July 20–23, while Jason Adair and Chief Accounting Officer Dana Boyle sold smaller amounts on July 27. The latter transactions were conducted under Rule 10b5-1 plans to cover tax withholding, reducing their negative significance; nevertheless, the director’s larger sales may encourage profit-taking concerns. Liquidia Insider Sales SEC Filing

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).